Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day
BOSTON, November 8, 2022 – Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer, and John Trzupek, M.B.A., Ph.D., chief operating officer, will participate in a fireside chat at Guggenheim’s 4th Annual Immunology and Neurology Day on Monday, November 14, 2022, at 9:00 a.m. ET in New York, NY.
About Abata Therapeutics
Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. In addition to its lead program in progressive multiple sclerosis (MS), Abata has programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM) – two additional tissue-specific autoimmune diseases with substantial unmet need and a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Cambridge, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information.
Stern Investor Relations, Inc.